A Phase I Study of the mTOR Inhibitor Temsirolimus in Combination with the HDAC Inhibitor Vorinostat in Patients with Metastatic Prostate Cancer

This is a Phase I research study. "Phase I" means that the combination of the study drugs is either being studied for the first time in humans or has been tested a limited number of times in humans. In this Phase I study we will start at the low doses of vorinostat and temsirolimus and slowly increase the amount of drugs that is given to the study subjects until the side effects of the combination are too high. This means that not all people in the study will get the same doses of vorinostat and temsirolimus. Doses at the beginning of the study will be lower than doses at the end of the study. Because of the design of the study, some people will probably get doses that are too low to have an effect, and other people will probably get doses that cause side effects.

Study Number: 

I 150709

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.